Find the latest Altimmune, Inc. (3G0.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Altimmune Inc (3G0.DU) stock quote, history, news and other vital information to help you with your stock trading and investing.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Altimmune (ALT) said Thursday that its phase 2b trial of its product candidate pemvidutide has met i The recent price decline of 12% in Altimmune, Inc.'s ( NASDAQ:ALT ) stock may have disappointed ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...